Clinical Trial Update: A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group [Phase 1]

View source ↗

Summary

A Phase 1 study evaluated the safety and pharmacokinetics of glyceryl tri-(4-phenylbutyrate) given as a single dose and twice-daily dosing for seven days in sub…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Encephalopathy
• Urea Cycle Disorders

Drugs mentioned

• Glyceryl tri-(4-phenylbutyrate) (Glyceryl tri-(4-phenylbutyrate))

Snippet

Sponsor: Amgen | Conditions: Hepatic Encephalopathy, Urea Cycle Disorders | Phase 1 | Status: COMPLETED